Q2 2024 Bausch Health Companies Inc Earnings Call Transcript
Key Points
- Bausch Health Companies Inc (BHC) reported its fifth consecutive quarter of year-over-year growth in both revenue and adjusted EBITDA.
- Revenues for the second quarter of 2024, excluding Bausch + Lomb, were $1.19 billion, marking a 5% increase on a reported basis and 6% on an organic basis compared to the same period last year.
- The company saw significant organic growth in its segments, with Xifaxan achieving 10% growth and Solta achieving 19% growth, particularly in the Asia Pacific region.
- Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb, increased by approximately 8% compared to the prior year.
- Bausch Health Companies Inc (BHC) has made strategic leadership changes, including the appointment of Aimee Lenar as Executive Vice President, US Pharma, and JJ Charhon as the new Chief Financial Officer, to drive transformation and growth.
- The company is facing pricing pressure and volume declines in its non-promoted portfolio within the Salix segment.
- Relistor experienced a 9% decline in revenue due to lower net pricing and softer demand.
- Trulance revenues declined approximately 50% year-over-year, largely due to net pricing pressure.
- The generics business saw an 11% decline in revenue on a reported basis, reflecting the highly competitive nature of the market.
- Concerns were raised about the company's leverage and debt maturities, with significant maturities approaching around the same time as Xifaxan's potential loss of exclusivity.
Greetings! Welcome to the Bausch Health second quarter 2024 earnings call. (Operator Instructions) Please note this conference is being recorded.
I would now like to turn the conference over to your host, Garen Sarafian, Investor Relations at Bausch. You may begin.
Good morning, and welcome to Bausch Health second quarter 2024 earnings conference call. Participating in today's call are Thomas Appio, Chief Executive Officer of Bausch Health; and John Barresi, Interim Chief Financial Officer.
Before we begin, I'd like to remind you that our presentation today contains forward-looking information. We ask you to take a moment to read the forward-looking statements disclaimer at the beginning of this slide that accompanies this presentation, as it contains important information.
Our actual results may vary materially from those expressed or implied in our forward-looking statements, and you should not place undue reliance on any forward-looking statements. Please refer to our SEC filings
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
